{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-24-041325","form_type":"8-K","ticker":"NKTR","cik":"0000906709","company_name":"NEKTAR THERAPEUTICS","filed_at":"2024-05-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:22.394239+00:00","generated_at":"2026-06-02T08:10:35.751702+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Nektar Q1 net loss narrows to $36.8M; REZPEG Phase 2b on track for H1 2025 data","bullets":["Revenue flat at $21.6M; net loss of $36.8M ($0.19/share) vs $137M loss YoY, improved on lower costs.","Cash and securities $326M; expects to fund operations into Q3 2026.","R&D expense $27.4M, down from $30.5M YoY; G&A $20.1M vs $21.1M.","Phase 2b REZPEG studies in atopic dermatitis and alopecia areata enrolling; topline data H1 2025.","Raised $30M gross via private placement in March 2024 with TCG Crossover Fund."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-24-041325","json":"https://secwatch.observer/filing/0001213900-24-041325.json","markdown":"https://secwatch.observer/filing/0001213900-24-041325.md","text":"https://secwatch.observer/filing/0001213900-24-041325.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/906709/000121390024041325/0001213900-24-041325-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/906709/000121390024041325/ea0205626-8k_nektar.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T08:10:35.751702+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"5978851833c4c743f4cd522222bb26a3d3591dd8","claim":"NEKTAR THERAPEUTICS reported first quarter ended March 31, 2024 results: revenue $21.6 million, net income $36.8 million or $0.19 basic and diluted loss per share, EPS $0.19 basic and diluted loss per share.","evidence_excerpt":"the TNFR2 receptor is progressing through IND-enabling studies to support entering the clinic next year.” Summary of Financial Results Revenue in the first quarter of 2024 was $21.6 million as compared to the same $21.6 million in the first quarter of 2023. Total operating costs and expenses in the first quarter of 2024 were $57.1 million as compared to $156.3","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/906709/000121390024041325/0001213900-24-041325-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended March 31, 2024"},{"label":"Revenue","value":"$21.6 million"},{"label":"Net income","value":"$36.8 million or $0.19 basic and diluted loss per share"},{"label":"EPS","value":"$0.19 basic and diluted loss per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}